Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers.
Jikuya R, Murakami K, Nishiyama A, Kato I, Furuya M, Nakabayashi J, Ramilowski JA, Hamanoue H, Maejima K, Fujita M, Mitome T, Ohtake S, Noguchi G, Kawaura S, Odaka H, Kawahara T, Komeya M, Shinoki R, Ueno D, Ito H, Ito Y, Muraoka K, Hayashi N, Kondo K, Nakaigawa N, Hatano K, Baba M, Suda T, Kodama T, Fujii S, Makiyama K, Yao M, Shuch BM, Schmidt LS, Linehan WM, Nakagawa H, Tamura T, Hasumi H. Jikuya R, et al. Among authors: ueno d. iScience. 2022 May 25;25(6):104463. doi: 10.1016/j.isci.2022.104463. eCollection 2022 Jun 17. iScience. 2022. PMID: 35874919 Free PMC article.
Glutamine and the Tumor Immune Microenvironment.
Faiena I, Ueno D, Shuch B. Faiena I, et al. Among authors: ueno d. Eur Urol. 2019 May;75(5):764-765. doi: 10.1016/j.eururo.2019.01.015. Epub 2019 Jan 30. Eur Urol. 2019. PMID: 30711333 No abstract available.
FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.
Nakaigawa N, Kondo K, Tateishi U, Minamimoto R, Kaneta T, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Kubota Y, Inoue T, Yao M. Nakaigawa N, et al. Among authors: ueno d. BMC Cancer. 2016 Feb 8;16:67. doi: 10.1186/s12885-016-2097-4. BMC Cancer. 2016. PMID: 26857818 Free PMC article.
The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N, Kondo K, Ueno D, Namura K, Makiyama K, Kobayashi K, Shioi K, Ikeda I, Kishida T, Kaneta T, Minamimoto R, Tateishi U, Inoue T, Yao M. Nakaigawa N, et al. Among authors: ueno d. BMC Cancer. 2017 Jan 9;17(1):39. doi: 10.1186/s12885-016-3044-0. BMC Cancer. 2017. PMID: 28068944 Free PMC article.
FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Nakaigawa N, Kondo K, Kaneta T, Tateishi U, Minamimoto R, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Hayashi N, Osaka K, Muraoka K, Izumi K, Kawahara T, Teranishi JI, Miyoshi Y, Yumura Y, Uemura H, Inoue T, Yao M. Nakaigawa N, et al. Among authors: ueno d. Cancer Chemother Pharmacol. 2018 Apr;81(4):739-744. doi: 10.1007/s00280-018-3542-7. Epub 2018 Feb 20. Cancer Chemother Pharmacol. 2018. PMID: 29464355
One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H, Kondo K, Kawahara T, Kaneta T, Tateishi U, Ueno D, Namura K, Kobayashi K, Miyoshi Y, Yumura Y, Makiyama K, Hayashi N, Hasumi H, Osaka K, Yokomizo Y, Teranishi JI, Hattori Y, Inoue T, Uemura H, Yao M, Nakaigawa N. Ito H, et al. Among authors: ueno d. Cancer Chemother Pharmacol. 2017 May;79(5):855-861. doi: 10.1007/s00280-017-3275-z. Epub 2017 Mar 22. Cancer Chemother Pharmacol. 2017. PMID: 28331985
Time-dependent change in relapse sites of renal cell carcinoma after curative surgery.
Noguchi G, Nakaigawa N, Taguri M, Tsutsumi S, Saito Y, Fukui S, Yasui M, Tokita T, Mitome T, Tatenuma T, Kuroda S, Abe K, Ueno D, Namura K, Umemoto S, Takizawa A, Ohta J, Ueki T, Watanabe T, Kobayashi K, Kondo K, Kishida T, Kanno H, Kitami K, Yamanaka T, Yao M. Noguchi G, et al. Among authors: ueno d. Clin Exp Metastasis. 2018 Feb;35(1-2):69-75. doi: 10.1007/s10585-018-9883-0. Epub 2018 Mar 7. Clin Exp Metastasis. 2018. PMID: 29516208
The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.
Kakizoe M, Yao M, Tateishi U, Minamimoto R, Ueno D, Namura K, Makiyama K, Hayashi N, Sano F, Kishida T, Kobayashi K, Noguchi S, Ikeda I, Ohgo Y, Taguri M, Morita S, Inoue T, Kubota Y, Nakaigawa N. Kakizoe M, et al. Among authors: ueno d. BMC Cancer. 2014 Jun 2;14:390. doi: 10.1186/1471-2407-14-390. BMC Cancer. 2014. PMID: 24885730 Free PMC article.
155 results